{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:07Z","timestamp":1792513087195,"version":"4.5.0"},"reference-count":229,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bcp.2024.116259","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T16:10:41Z","timestamp":1714752641000},"page":"116259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update"],"prefix":"10.1016","volume":"228","author":[{"given":"Kyung-Soo","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Kyung","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-1795","authenticated-orcid":false,"given":"Young-Joon","family":"Surh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116259_b0005","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2024.116259_b0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.molcel.2014.03.030","article-title":"Stress, inflammation, and defense of homeostasis","volume":"54","author":"Chovatiya","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jtcvs.2014.11.070","article-title":"Inflammation: the classic double-edged sword","volume":"149","author":"Kurlansky","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.bcp.2024.116259_b0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00281-019-00771-2","article-title":"Resolution of inflammation: from basic concepts to clinical application","volume":"41","author":"Neurath","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bcp.2024.116259_b0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri3362","article-title":"The resolution of inflammation","volume":"13","author":"Buckley","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2010.02.029","article-title":"Nonresolving inflammation","volume":"140","author":"Nathan","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0035","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.bcp.2004.05.031","article-title":"Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention","volume":"68","author":"Chun","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116259_b0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2024.116259_b0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15430\/JCP.2020.25.1.27","article-title":"Effects of genetic and pharmacologic inhibition of COX-2 on colitis-associated carcinogenesis in mice","volume":"25","author":"Lee","year":"2020","journal-title":"J. Cancer Prev."},{"key":"10.1016\/j.bcp.2024.116259_b0050","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/215158","article-title":"The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies","volume":"2010","author":"Sobolewski","year":"2010","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.bcp.2024.116259_b0055","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.2005.09.051","article-title":"COX-2: a molecular target for colorectal cancer prevention","volume":"23","author":"Brown","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040594","article-title":"Non-steroidal anti-inflammatory drugs in colorectal cancer chemoprevention","volume":"13","author":"Maniewska","year":"2021","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116259_b0065","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2613.2006.00507.x","article-title":"Chronic inflammation: a failure of resolution?","volume":"88","author":"Lawrence","year":"2007","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.bcp.2024.116259_b0075","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/cddiscovery.2015.56","article-title":"Secondary necrotic neutrophils release interleukin-16C and macrophage migration inhibitory factor from stores in the cytosol","volume":"1","author":"Roth","year":"2015","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2024.116259_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1677\/joe.0.1780029","article-title":"Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation","volume":"178","author":"Heasman","year":"2003","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bcp.2024.116259_b0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1042\/bse0390105","article-title":"The final step in programmed cell death: phagocytes carry apoptotic cells to the grave","volume":"39","author":"deCathelineau","year":"2003","journal-title":"Essays Biochem."},{"key":"10.1016\/j.bcp.2024.116259_b0090","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10495-017-1413-z","article-title":"The immune response to secondary necrotic cells","volume":"22","author":"Sachet","year":"2017","journal-title":"Apoptosis"},{"key":"10.1016\/j.bcp.2024.116259_b0095","doi-asserted-by":"crossref","first-page":"S5-11","DOI":"10.1164\/ajrccm.160.supplement_1.4","article-title":"Granulocyte apoptosis and its role in the resolution and control of lung inflammation","volume":"160","author":"Haslett","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2024.116259_b0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1097-2765(04)00237-0","article-title":"Clearance of apoptotic cells: getting rid of the corpses","volume":"14","author":"Lauber","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0105","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.20101157","article-title":"Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums","volume":"207","author":"Ravichandran","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.immuni.2011.09.004","article-title":"Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways","volume":"35","author":"Ravichandran","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2024.116259_b0115","first-page":"949","article-title":"CD36 promotes adipocyte differentiation and adipogenesis","volume":"2012","author":"Christiaens","year":"1820","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bcp.2024.116259_b0120","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/emmm.201202382","article-title":"Resolution of inflammation: an integrated view","volume":"5","author":"Ortega-Gomez","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0125","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1084\/jem.20011794","article-title":"Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation","volume":"196","author":"Bellingan","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0130","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tips.2007.02.003","article-title":"Inflammation and cancer: a failure of resolution?","volume":"28","author":"Lawrence","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0135","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fimmu.2016.00160","article-title":"Resolution of inflammation: What controls its onset?","volume":"7","author":"Sugimoto","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41577-022-00761-w","article-title":"Tuning immunity through tissue mechanotransduction","volume":"23","author":"Du","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2006.02.016","article-title":"Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer","volume":"124","author":"Karin","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0150","first-page":"98","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2011","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0155","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: an ancient link with novel potentials","volume":"121","author":"Hussain","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-018-0048-z","article-title":"Role of nonresolving inflammation in hepatocellular carcinoma development and progression","volume":"2","author":"Yu","year":"2018","journal-title":"NPJ. Precis. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b0165","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/14712598.2011.592826","article-title":"Unresolved inflammation: 'immune tsunami' or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer","volume":"11","author":"Khatami","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bcp.2024.116259_b0170","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1172\/JCI80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2024.116259_b0175","doi-asserted-by":"crossref","first-page":"eabl5420","DOI":"10.1126\/sciadv.abl5420","article-title":"Aspirin activates resolution pathways to reprogram T cell and macrophage responses in colitis-associated colorectal cancer","volume":"8","author":"De Matteis","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2024.116259_b0180","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1038\/onc.2010.109","article-title":"Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer","volume":"29","author":"Danese","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116259_b0185","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0016-5085(95)90599-5","article-title":"Experimental models of inflammatory bowel disease","volume":"109","author":"Elson","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2024.116259_b0190","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcmgh.2015.01.006","article-title":"Experimental models of inflammatory bowel diseases","volume":"1","author":"Kiesler","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2024.116259_b0195","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5217\/ir.2023.00029","article-title":"Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer","volume":"21","author":"Lee","year":"2023","journal-title":"Intest. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0200","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1349-7006.2003.tb01386.x","article-title":"A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate","volume":"94","author":"Tanaka","year":"2003","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0205","series-title":"The Azoxymethane plus Dextran Sulfate Sodium-Induced Mouse Colon Cancer Model for the Study of Dietary Chemoprevention of Inflammation-Associated Carcinogenesis","author":"Lee","year":"2014"},{"key":"10.1016\/j.bcp.2024.116259_b0210","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1567-5769(01)00102-3","article-title":"Inflammation, carcinogenesis and cancer","volume":"1","author":"Fitzpatrick","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116259_b0215","first-page":"50","article-title":"Inflammation and cancer, Environ. Health","volume":"23","author":"Murata","year":"2018","journal-title":"Prev. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107670","article-title":"Carcinogenesis: Failure of resolution of inflammation?","volume":"218","author":"Fishbein","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116259_b0225","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116259_b0230","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"Suppl","key":"10.1016\/j.bcp.2024.116259_b0235","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.semcancer.2015.03.006","article-title":"A multi-targeted approach to suppress tumor-promoting inflammation","volume":"35","author":"Samadi","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2024.116259_b0240","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/431405a","article-title":"Cancer: an inflammatory link","volume":"431","author":"Balkwill","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116259_b0245","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature02924","article-title":"NF-\u03baB functions as a tumour promoter in inflammation-associated cancer","volume":"431","author":"Pikarsky","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116259_b0250","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.07.013","article-title":"IKK\u03b2 links inflammation and tumorigenesis in a mouse model of colitis-associated cancer","volume":"118","author":"Greten","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0255","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/febs.14210","article-title":"Nonresolving macrophage-mediated inflammation in malignancy","volume":"285","author":"Murray","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2024.116259_b0260","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0265","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","article-title":"TGF-\u03b2suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling","volume":"21","author":"Becker","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2024.116259_b0270","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2024.116259_b0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2008.03.002","article-title":"Inflammation: gearing the journey to cancer","volume":"659","author":"Kundu","year":"2008","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0280","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0290","doi-asserted-by":"crossref","unstructured":"B. Mirlekar, Tumor promoting roles of IL-10, TGF-beta, IL-4, and IL-35: Its implications in cancer immunotherapy, SAGE Open Med. 10 (2022) 20503121211069012.","DOI":"10.1177\/20503121211069012"},{"key":"10.1016\/j.bcp.2024.116259_b0295","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-030-96376-7_3","article-title":"Engaging pattern recognition receptors in solid tumors to generate systemic antitumor immunity","volume":"183","author":"Brown","year":"2022","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105017","article-title":"Promising targets based on pattern recognition receptors for cancer immunotherapy","volume":"159","author":"Bai","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0305","first-page":"71","article-title":"Resolution of cancer-promoting inflammation: A new approach for anticancer therapy","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0310","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0009-9120(90)90051-U","article-title":"Phospholipases in biology and medicine","volume":"23","author":"Kaiser","year":"1990","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bcp.2024.116259_b0315","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fphar.2013.00034","article-title":"COX-2 in cancer: Gordian knot or Achilles heel?","volume":"4","author":"Stasinopoulos","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116259_b0320","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00042737-200406000-00017","article-title":"The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas","volume":"16","author":"Sheehan","year":"2004","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2024.116259_b0325","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jama.282.13.1254","article-title":"The relationship between cyclooxygenase-2 expression and colorectal cancer","volume":"282","author":"Sheehan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2024.116259_b0330","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3892\/ol.2013.1426","article-title":"Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients","volume":"6","author":"Lin","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2024.116259_b0335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/CBM-2007-3306","article-title":"Cyclooxygenase-2 as target for chemopreventive interventions: new approaches","volume":"3","author":"Dvory-Sobol","year":"2007","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.bcp.2024.116259_b0340","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/bcr1678","article-title":"Inflammation and breast cancer. Cyclooxygenase\/prostaglandin signaling and breast cancer","volume":"9","author":"Howe","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0345","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcp.2024.116259_b0350","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-007-9641-5","article-title":"The role of cyclooxygenase-2 in breast cancer: review","volume":"109","author":"Singh-Ranger","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2024.116259_b0355","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1046\/j.1460-9568.2000.00218.x","article-title":"Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A","volume":"12","author":"Smith","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2024.116259_b0360","first-page":"434","article-title":"Prostaglandin E2 and cancer: Insight into tumor progression and immunity","volume":"9","author":"Finetti","year":"2020","journal-title":"Biology (basel)"},{"key":"10.1016\/j.bcp.2024.116259_b0365","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.3390\/ijms20246254","article-title":"Prostaglandin E2\/EP signaling in the tumor microenvironment of colorectal cancer","volume":"20","author":"Mizuno","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0370","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/gut.35.5.675","article-title":"Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2","volume":"35","author":"Pugh","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2024.116259_b0375","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00432-019-02883-6","article-title":"The application of ApcMin\/+ mouse model in colorectal tumor researches","volume":"145","author":"Ren","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b0380","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccr.2004.08.011","article-title":"Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta","volume":"6","author":"Wang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0385","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/carcin\/bgg033","article-title":"Enhancement of colon carcinogenesis by prostaglandin E2 administration","volume":"24","author":"Kawamori","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2024.116259_b0390","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2021.09.059","article-title":"Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer","volume":"161","author":"Wang","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2024.116259_b0395","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbrc.2008.10.179","article-title":"Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer","volume":"378","author":"Patel","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116259_b0400","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1053\/j.gastro.2015.07.064","article-title":"Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice","volume":"149","author":"Wang","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2024.116259_b0405","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12885-016-2466-z","article-title":"The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model","volume":"16","author":"Bellamkonda","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b0410","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/15384047.2022.2104561","article-title":"Colorectal cancer chemoprevention: is aspirin still in the game?","volume":"23","author":"Grancher","year":"2022","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2024.116259_b0415","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1940-6207.CAPR-22-0038","article-title":"Role of prostaglandin E2 in the progression of gastrointestinal cancer","volume":"15","author":"Wilson","year":"2022","journal-title":"Cancer Prev. Res. (phila)"},{"key":"10.1016\/j.bcp.2024.116259_b0420","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2024.116259_b0425","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1158\/0008-5472.CAN-06-0425","article-title":"Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia","volume":"66","author":"Kaidi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106338","article-title":"Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer","volume":"144","author":"Karpisheh","year":"2019","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.bcp.2024.116259_b0435","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/cas.12901","article-title":"Inflammation in gastric cancer: Interplay of the COX-2\/prostaglandin E2 and Toll-like receptor\/MyD88 pathways","volume":"107","author":"Echizen","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0440","first-page":"1353","article-title":"A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon","volume":"17","author":"Harada","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116259_b0445","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fmicb.2017.00538","article-title":"Role of modulator of inflammation cyclooxygenase-2 in gammaherpesvirus mediated tumorigenesis","volume":"8","author":"Gandhi","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bcp.2024.116259_b0450","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50380","article-title":"Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis","volume":"38","author":"Leng","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2024.116259_b0455","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.1038\/sj.onc.1203286","article-title":"The role of cyclooxygenases in inflammation, cancer, and development","volume":"18","author":"Williams","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116259_b0460","doi-asserted-by":"crossref","first-page":"1099811","DOI":"10.3389\/fonc.2023.1099811","article-title":"Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells","volume":"13","author":"Jin","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b0465","doi-asserted-by":"crossref","first-page":"eabd7954","DOI":"10.1126\/sciadv.abd7954","article-title":"Prostaglandin E2 promotes intestinal inflammation via inhibiting microbiota-dependent regulatory T cells","volume":"7","author":"Crittenden","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2024.116259_b0470","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1940-6207.CAPR-21-0572","article-title":"The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas","volume":"15","author":"Wei","year":"2022","journal-title":"Cancer Prev. Res. (phila)"},{"key":"10.1016\/j.bcp.2024.116259_b0475","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2024.116259_b0480","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0165-6147(03)00162-7","article-title":"Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer?","volume":"24","author":"Fujino","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0485","doi-asserted-by":"crossref","first-page":"39672","DOI":"10.1074\/jbc.M110.117689","article-title":"The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and beta-arrestin1-dependent signaling pathways","volume":"285","author":"Chun","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116259_b0490","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/onc.2015.283","article-title":"Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth","volume":"35","author":"Schumacher","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116259_b0495","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.lfs.2009.12.009","article-title":"Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells","volume":"86","author":"Bai","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0500","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1111\/bph.16148","article-title":"Complementary roles of EP2 and EP4 receptors in malignant glioma","volume":"180","author":"Qiu","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116259_b0505","first-page":"5093","article-title":"Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis","volume":"59","author":"Watanabe","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0510","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.1116221","article-title":"Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis","volume":"310","author":"Castellone","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116259_b0515","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/0008-5472.CAN-15-0125","article-title":"Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth","volume":"75","author":"Ma","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0520","first-page":"28","article-title":"Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis","volume":"62","author":"Mutoh","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0525","doi-asserted-by":"crossref","first-page":"12538","DOI":"10.1074\/jbc.M800105200","article-title":"Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo","volume":"283","author":"Macias-Perez","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116259_b0530","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/gut.2003.028787","article-title":"Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development","volume":"53","author":"Shoji","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2024.116259_b0535","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/1871520619666190227174137","article-title":"Microsomal prostaglandin E2 synthase-1 as a new macromolecular drug target in the prevention of inflammation and cancer","volume":"19","author":"Bulbul","year":"2019","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bcp.2024.116259_b0540","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/15353702231179926","article-title":"The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders","volume":"248","author":"Sluter","year":"2023","journal-title":"Exp. Biol. Med. (maywood)"},{"key":"10.1016\/j.bcp.2024.116259_b0545","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.biochi.2010.02.006","article-title":"mPGES-1 as a target for cancer suppression: A comprehensive invited review \u201cPhospholipase A2 and lipid mediators\u201d","volume":"92","author":"Nakanishi","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.bcp.2024.116259_b0550","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00428-009-0777-z","article-title":"Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients","volume":"454","author":"Seo","year":"2009","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bcp.2024.116259_b0555","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/0008-5472.CAN-07-6100","article-title":"Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis","volume":"68","author":"Nakanishi","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0560","first-page":"4705","article-title":"Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice","volume":"60","author":"Chulada","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0565","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","article-title":"Suppression of intestinal polyposis in Apc\u0394716 knockout mice by inhibition of cyclooxygenase 2","volume":"87","author":"Oshima","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116259_b0570","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-13-1573","article-title":"NSAIDs inhibit tumorigenesis, but how?","volume":"20","author":"Gurpinar","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0575","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/carcin\/20.4.635","article-title":"Relationship of \u03b2-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice","volume":"20","author":"McEntee","year":"1999","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2024.116259_b0580","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/cam4.2881","article-title":"Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis","volume":"9","author":"Rohwer","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2024.116259_b0585","first-page":"403","article-title":"Prostaglandin E2 protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min\/+) mice","volume":"62","author":"Hansen-Petrik","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0590","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","article-title":"Aspirin in the chemoprevention of colorectal neoplasia: an overview","volume":"5","author":"Chan","year":"2012","journal-title":"Cancer Prev. Res. (phila)"},{"key":"10.1016\/j.bcp.2024.116259_b0595","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1568009043481632","article-title":"NSAIDs and chemoprevention","volume":"4","author":"Rao","year":"2004","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2024.116259_b0600","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcp.2024.116259_b0605","doi-asserted-by":"crossref","first-page":"20027","DOI":"10.1073\/pnas.1010430107","article-title":"Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis","volume":"107","author":"Qiu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2024.116259_b0610","first-page":"519","article-title":"Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH\/HES1 and activating PPARG in colorectal cancer","volume":"134","author":"Moon","year":"2014","journal-title":"Int. J."},{"key":"10.1016\/j.bcp.2024.116259_b0615","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41416-020-0906-7","article-title":"Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner","volume":"123","author":"Shen","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b0620","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/bmb\/ldw028","article-title":"The role of aspirin in preventing colorectal cancer","volume":"119","author":"Burn","year":"2016","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.bcp.2024.116259_b0625","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bpg.2012.01.009","article-title":"Aspirin and the prevention of colorectal cancer","volume":"26","author":"Ferrandez","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.bcp.2024.116259_b0630","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.3748\/wjg.v22.i13.3679","article-title":"Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?","volume":"22","author":"Burr","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2024.116259_b0635","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b0640","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0645","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0650","doi-asserted-by":"crossref","first-page":"713","DOI":"10.7326\/0003-4819-128-9-199805010-00003","article-title":"Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study","volume":"128","author":"Sturmer","year":"1998","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.bcp.2024.116259_b0655","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial","volume":"294","author":"Cook","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2024.116259_b0660","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2024.116259_b0665","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00011-019-01300-5","article-title":"Acute changes in colonic PGE2 levels as a biomarker of efficacy after treatment of the Pirc (F344\/NTac-Apc (am1137)) rat with celecoxib","volume":"69","author":"Yun","year":"2020","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0670","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1940-6207.CAPR-21-0227","article-title":"COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of type I tumor-infiltrating lymphocytes","volume":"15","author":"Cecil","year":"2022","journal-title":"Cancer Prev. Res. (phila)"},{"key":"10.1016\/j.bcp.2024.116259_b0675","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/jnci\/96.23.1734","article-title":"Vioxx withdrawal alarms cancer prevention researchers","volume":"96","author":"Vanchieri","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcp.2024.116259_b0680","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0685","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0690","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0695","first-page":"310","article-title":"Adenoma Prevention with Celecoxib Study, Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial, Cancer Prev","volume":"2","author":"Bertagnolli","year":"2009","journal-title":"Res. (phila)"},{"key":"10.1016\/j.bcp.2024.116259_b0700","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","article-title":"Cross Trial Safety Assessment, Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis","volume":"117","author":"Solomon","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2024.116259_b0705","first-page":"4756","article-title":"A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients","volume":"9","author":"Higuchi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0710","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","article-title":"A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas","volume":"131","author":"Baron","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2024.116259_b0715","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Adenomatous Polyp Prevention on Vioxx Trial, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0720","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djn187","article-title":"Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention","volume":"100","author":"Tuma","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcp.2024.116259_b0725","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.mehy.2011.04.002","article-title":"The role of COX-2 and Nrf2\/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging","volume":"77","author":"Luo","year":"2011","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bcp.2024.116259_b0730","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/9550","article-title":"Inducible cyclooxygenase may have anti-inflammatory properties","volume":"5","author":"Gilroy","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0735","article-title":"Physiology of the inflammatory response: the time course as a guide for anti-inflammatory intervention","volume":"10","author":"Silva","year":"2011","journal-title":"Odontol. Cl\u00edn-Cient."},{"key":"10.1016\/j.bcp.2024.116259_b0740","first-page":"3418975","article-title":"Role of Nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion","volume":"2019","author":"Wong","year":"2019","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0745","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bcp.2011.07.100","article-title":"15-Deoxy-\u039412,14-prostaglandin J2, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling","volume":"82","author":"Surh","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116259_b0750","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.4049\/jimmunol.165.11.6525","article-title":"Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages","volume":"165","author":"Hortelano","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0755","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/47520","article-title":"Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I\u03baB kinase","volume":"403","author":"Rossi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116259_b0760","doi-asserted-by":"crossref","first-page":"20979","DOI":"10.1073\/pnas.0707394104","article-title":"Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxy-\u039412,14-prostaglandin J2","volume":"104","author":"Rajakariar","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2024.116259_b0765","article-title":"15-Deoxy-\u039412,14-prostaglandin J2 promotes resolution of experimentally induced colitis","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108183","article-title":"15-Deoxy-\u039412,14-prostaglandin J2 ameliorates dextran sulfate sodium-induced colitis in mice through heme oxygenase-1 induction","volume":"677","author":"Takagi","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2024.116259_b0775","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5009\/gnl210058","article-title":"Potential role of heme oxygenase-1 in the resolution of experimentally induced colitis through regulation of macrophage polarization","volume":"16","author":"Gwak","year":"2022","journal-title":"Gut Liver"},{"key":"10.1016\/j.bcp.2024.116259_b0780","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/152308602753666307","article-title":"Activation of the mouse heme oxygenase-1 gene by 15-deoxy-\u039412,14-prostaglandin J2 is mediated by the stress response elements and transcription factor Nrf2","volume":"4","author":"Gong","year":"2002","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bcp.2024.116259_b0785","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4161\/cbt.10.8.12896","article-title":"15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer","volume":"10","author":"Liu","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2024.116259_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108176","article-title":"Recent advances in studies of 15-PGDH as a key enzyme for the degradation of prostaglandins","volume":"101","author":"Sun","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116259_b0795","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1074\/jbc.M411221200","article-title":"15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer","volume":"280","author":"Backlund","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116259_b0800","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5217\/ir.2017.15.1.75","article-title":"15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue","volume":"15","author":"Yang","year":"2017","journal-title":"Intest. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0805","doi-asserted-by":"crossref","first-page":"12098","DOI":"10.1073\/pnas.0603235103","article-title":"15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis","volume":"103","author":"Myung","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2024.116259_b0810","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1073\/pnas.0902367106","article-title":"15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors","volume":"106","author":"Yan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2024.116259_b0815","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI69672","article-title":"Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis","volume":"124","author":"Choi","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2024.116259_b0820","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s10620-014-3478-7","article-title":"Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease","volume":"60","author":"Dai","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0825","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1158\/0008-5472.CAN-08-2893","article-title":"Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer","volume":"68","author":"Backlund","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0830","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.4049\/jimmunol.0802358","article-title":"Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer","volume":"182","author":"Eruslanov","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0835","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/carcin\/bgm297","article-title":"Expression of 15-PGDH is downregulated by COX-2 in gastric cancer","volume":"29","author":"Liu","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2024.116259_b0840","doi-asserted-by":"crossref","first-page":"G559","DOI":"10.1152\/ajpgi.00133.2009","article-title":"Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes","volume":"297","author":"Miyaki","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcp.2024.116259_b0845","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.21873\/anticanres.16043","article-title":"15-Prostaglandin dehydrogenase inhibition enhances colon cancer metastasis by up-regulation of epithelial-to-mesenchymal transition genes","volume":"42","author":"Kim","year":"2022","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b0850","doi-asserted-by":"crossref","first-page":"18162","DOI":"10.1074\/jbc.M702289200","article-title":"Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation","volume":"282","author":"Chou","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116259_b0855","doi-asserted-by":"crossref","first-page":"e0176106","DOI":"10.1371\/journal.pone.0176106","article-title":"15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury","volume":"12","author":"Yao","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116259_b0860","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.freeradbiomed.2017.11.016","article-title":"Targeting the 15-keto-PGE2-PTGR2 axis modulates systemic inflammation and survival in experimental sepsis","volume":"115","author":"Chen","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0865","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2018.06.013","article-title":"Canonical and non-canonical mechanisms of Nrf2 activation","volume":"134","author":"Silva-Islas","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2024.116259_b0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108162","article-title":"15-Keto prostaglandin E2 induces heme oxygenase-1 expression through activation of Nrf2 in human colon epithelial CCD 841 CoN cells","volume":"679","author":"Lee","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2024.116259_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101175","article-title":"15-Keto prostaglandin E2 suppresses STAT3 signaling and inhibits breast cancer cell growth and progression","volume":"23","author":"Lee","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2024.116259_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107997","article-title":"15-Keto-PGE2 alleviates nonalcoholic steatohepatitis through its covalent modification of NF-\u03baB factors","volume":"26","author":"Hee","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.bcp.2024.116259_b0885","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nchembio.367","article-title":"Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids","volume":"6","author":"Groeger","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116259_b0890","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/501792","article-title":"Endogenous generation and signaling actions of omega-3 fatty acid electrophilic derivatives","volume":"2015","author":"Cipollina","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bcp.2024.116259_b0895","first-page":"2299","article-title":"Dual anti-oxidant and anti-inflammatory actions of the electrophilic cyclooxygenase-2-derived 17-oxo-DHA in lipopolysaccharide- and cigarette smoke-induced inflammation","volume":"2014","author":"Cipollina","year":"1840","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bcp.2024.116259_b0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108156","article-title":"17-Oxo-docosahexaenoic acid induces Nrf2-mediated expression of heme oxygenase-1 in mouse skin in vivo and in cultured murine epidermal cells","volume":"679","author":"Jamil","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2024.116259_b0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102666","article-title":"Protective effects of an electrophilic metabolite of docosahexaenoic acid on UVB-induced oxidative cell death, dermatitis, and carcinogenesis","volume":"62","author":"Kim","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2024.116259_b0910","doi-asserted-by":"crossref","first-page":"37625","DOI":"10.1038\/srep37625","article-title":"17-oxo-DHA displays additive anti-inflammatory effects with fluticasone propionate and inhibits the NLRP3 inflammasome","volume":"6","author":"Cipollina","year":"2016","journal-title":"Sci Rep."},{"key":"10.1016\/j.bcp.2024.116259_b0915","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/EBC20200018","article-title":"Specialized pro-resolving mediator network: an update on production and actions","volume":"64","author":"Chiang","year":"2020","journal-title":"Essays Biochem."},{"key":"10.1016\/j.bcp.2024.116259_b0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2023.106718","article-title":"Resolvins and cysteinyl-containing pro-resolving mediators activate resolution of infectious inflammation and tissue regeneration","volume":"166","author":"Serhan","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.bcp.2024.116259_b0925","doi-asserted-by":"crossref","first-page":"155","DOI":"10.12998\/wjcc.v4.i7.155","article-title":"Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer","volume":"4","author":"Moro","year":"2016","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.bcp.2024.116259_b0930","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10555-023-10091-5","article-title":"Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?","volume":"42","author":"Serhan","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2024.116259_b0935","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20020760","article-title":"Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals","volume":"196","author":"Serhan","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2024.116259_b0940","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.3390\/ijms241612623","article-title":"The role of specialized pro-resolving lipid mediators in inflammation-induced carcinogenesis","volume":"24","author":"Torres","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0945","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.3390\/ijms23031432","article-title":"NSAIDs and cancer resolution: New paradigms beyond cyclooxygenase","volume":"23","author":"Kolawole","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b0950","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.702785","article-title":"Specialized pro-resolving mediators mitigate cancer-related inflammation: Role of tumor-associated macrophages and therapeutic opportunities","volume":"12","author":"Lavy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116259_b0955","first-page":"e21432","article-title":"Resolvin D1 suppresses inflammation-associated tumorigenesis in the colon by inhibiting IL-6-induced mitotic spindle abnormality","volume":"35","author":"Lee","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2024.116259_b0960","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143333","article-title":"The impact of resolution of inflammation on tumor microenvironment: Exploring new ways to control cancer progression","volume":"14","author":"Liotti","year":"2022","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116259_b0965","article-title":"Lipoxins and resolvins in patients with pancreatic cancer: A preliminary report","volume":"11","author":"Blogowski","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b0970","series-title":"Molecular mechanisms and therapeutic potential of resolvins in cancer- current status and perspectives","author":"Tajbakhsh","year":"2023"},{"key":"10.1016\/j.bcp.2024.116259_b0975","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semcancer.2016.08.004","article-title":"Anti-inflammatory effects of docosahexaenoic acid: Implications for its cancer chemopreventive potential","volume":"40\u201341","author":"Yum","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2024.116259_b0980","first-page":"6","article-title":"DHA-enriched supplement ameliorates cancer-associated systemic inflammatory response via resolvin D1 production: a single institutional study","volume":"1","author":"T.K. Mohri Y, Imaoka H, Miki C, Fujikawa H, Shimura T, Toiyama Y, Araki T, Kusunoki M","year":"2016","journal-title":"Biomed. Res. Clin. Prac."},{"key":"10.1016\/j.bcp.2024.116259_b0985","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3892\/or.2015.4389","article-title":"Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-\u03baB activity","volume":"35","author":"Kuang","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116259_b0990","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126473","article-title":"Gene expression of the D-series resolvin pathway predicts activation of anti-tumor immunity and clinical outcomes in head and neck cancer","volume":"23","author":"Mattoscio","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2024.116259_b0995","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.20170681","article-title":"Resolvins suppress tumor growth and enhance cancer therapy","volume":"215","author":"Sulciner","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2024.116259_b1000","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1073\/pnas.1804000116","article-title":"Aspirin-triggered proresolving mediators stimulate resolution in cancer","volume":"116","author":"Gilligan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2024.116259_b1005","first-page":"4037","article-title":"Resolvin D1 stimulates efferocytosis through p50\/p50-mediated suppression of tumor necrosis factor-alpha expression","volume":"126","author":"Lee","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2024.116259_b1010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13046-021-01937-3","article-title":"Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes","volume":"40","author":"Mattoscio","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b1015","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.ajpath.2022.07.004","article-title":"Resolvin E1 reduces tumor growth in a xenograft model of lung cancer","volume":"192","author":"Kantarci","year":"2022","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2024.116259_b1020","first-page":"1","article-title":"Pro-resolving lipid mediators and anti-angiogenic therapy exhibit synergistic anti-tumor activity via resolvin receptor activation, Experimental Biology Meeting","author":"K.F. Hallisey VM, Moore J, Garung A","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2024.116259_b1025","article-title":"Resolvins inhibit breast tumor progression by countering cancer stem cells","author":"K.F. Duncan M, Kelly A, Rothenberger E, Huang S, Serhan CN, Panigrahy D","year":"2022","journal-title":"Experimental Biology Meeting"},{"key":"10.1016\/j.bcp.2024.116259_b1030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13046-019-1163-6","article-title":"Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP","volume":"38","author":"Sun","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b1035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: Signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.bcp.2024.116259_b1040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/gut.50.6.857","article-title":"A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis","volume":"50","author":"R.K. Phillips, M.H. Wallace, P.M. Lynch, E. Hawk, G.B. Gordon, B.P. Saunders, N. Wakabayashi, Y. Shen, S. Zimmerman, L. Godio, M. Rodrigues-Bigas, L.K. Su, J. Sherman, G. Kelloff, B. Levin, G. Steinbach, F.A.P.S. Group","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2024.116259_b1045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10549-010-1100-z","article-title":"Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer","volume":"123","author":"Martin","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2024.116259_b1050","first-page":"1483","article-title":"A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer","volume":"29","author":"Sooriakumaran","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b1055","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.2010.32.7254","article-title":"Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer","volume":"29","author":"Coombes","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b1060","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2010.29.6244","article-title":"Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial","volume":"28","author":"Midgley","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b1065","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1023\/A:1026130623186","article-title":"Rofecoxib reduces polyp recurrence in familial polyposis","volume":"48","author":"Hallak","year":"2003","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bcp.2024.116259_b1070","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.23288","article-title":"The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo","volume":"122","author":"Liu","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b1075","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12072-016-9704-y","article-title":"A randomized controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment","volume":"10","author":"Takami","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bcp.2024.116259_b1080","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/cam4.512","article-title":"A window-of-opportunity biomarker study of etodolac in resectable breast cancer","volume":"4","author":"Schwab","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2024.116259_b1085","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00404-011-1883-0","article-title":"Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers","volume":"284","author":"Hasegawa","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.bcp.2024.116259_b1090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10147-005-0548-z","article-title":"Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial","volume":"11","author":"Iwama","year":"2006","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b1095","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/cncr.29480","article-title":"Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer","volume":"121","author":"Reckamp","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b1100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clbc.2011.03.022","article-title":"Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer","volume":"11","author":"Lustberg","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b1105","doi-asserted-by":"crossref","first-page":"e16234","DOI":"10.1097\/MD.0000000000016234","article-title":"A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study","volume":"98","author":"Guo","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2024.116259_b1110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MCG.0b013e3181cda097","article-title":"Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer","volume":"44","author":"Lipton","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.bcp.2024.116259_b1115","first-page":"43","article-title":"Gemcitabine\/Irinotecan\/celecoxib in pancreatic cancer","volume":"18","author":"Lipton","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.bcp.2024.116259_b1120","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-17-0152","article-title":"Perioperative COX-2 and \u03b2-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a Phase-II randomized trial","volume":"23","author":"Shaashua","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116259_b1125","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/cncr.32950","article-title":"Perioperative COX-2 and \u03b2-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial","volume":"126","author":"Haldar","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b1130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbi.2018.05.014","article-title":"Perioperative inhibition of \u03b2-adrenergic and COX-2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome","volume":"73","author":"Haldar","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2024.116259_b1135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000082","article-title":"A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"9","author":"Gitlitz","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2024.116259_b1140","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/cncr.24902","article-title":"A phase 2 pilot trial of low-dose, continuous infusion, or \u201cmetronomic\u201d paclitaxel and oral celecoxib in patients with metastatic melanoma","volume":"116","author":"Bhatt","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2024.116259_b1145","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/annonc\/mdl311","article-title":"Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group","volume":"17","author":"Gogas","year":"2006","journal-title":"Ann. Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:18:28Z","timestamp":1731475108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224002429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":229,"alternative-id":["S0006295224002429"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116259","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116259"}}